Evidence map›Paper›PMID 33521873›Full record

ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2021

Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging.

Jamieson M Bourque, Christopher A Hanson, Denis Agostini, Timothy M Bateman, Jeroen J Bax, Rob S B Beanlands, Daniel S Berman, Ernest V Garcia, Gary V Heller, Juhani Knuuti and 3 more

2 registry-linked trialsAbstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03354273 phase3completednot on this map

A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease

TypeinterventionalSponsorGE HealthcareRan2018 to 2022Enrolled730ConditionsCoronary Artery Disease (CAD)ArmsPET MPI, SPECT MPI, Pharmacological stress agents
NCT07761728 enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging: The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

TypeobservationalSponsorUniversity of California, Los AngelesRan2025 to 2027Enrolled60ConditionsCoronary Artery Disease, Coronary Microvascular Disease
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Improved assessment of coronary artery disease in obese patients with flurpiridaz-Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026
    Trial
  2. Article
  3. Review
  4. Review
  5. Prevalence and nature of extracardiac findings in PET/CT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  6. Rest/stress myocardial perfusion imaging by positron emission tomography withJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  7. Progress ofAnnals of nuclear cardiology · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jamieson M BourqueDivision of Cardiovascular Medicine and the Cardiovascular Imaging Center, Department of Medicine, University of Virginia Health System, Box 800158, 1215 Lee Street, Charlottesville, VA, 22908, USA. jbourque@virginia.edu.
Christopher A HansonDivision of Cardiovascular Medicine and the Cardiovascular Imaging Center, Department of Medicine, University of Virginia Health System, Box 800158, 1215 Lee Street, Charlottesville, VA, 22908, USA.
Denis AgostiniNuclear Medicine Department, Normandy University Hospital, Caen, France.
Timothy M BatemanMid America Heart Institute, Saint Luke's Hospital, Kansas City, MO, USA.
Jeroen J BaxDepartment of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Rob S B BeanlandsDivision of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Daniel S BermanDepartment of Imaging (Division of Nuclear Medicine) Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ernest V GarciaDepartment of Radiology, Emory University School of Medicine, Atlanta, GA, USA.
Gary V HellerDepartment of Cardiology, Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ, USA.
Juhani KnuutiTurku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Nagara TamakiDepartment of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
James E UdelsonDivision of Cardiology, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
Jamshid MaddahiDivision of Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPositron emission tomography (PET) myocardial perfusion imaging (MPI) with the novel radiopharmaceutical Fluorine-18 Flurpiridaz has been shown in Phase 1, 2, and first Phase 3 clinical studies to be safe and effective in diagnosing coronary artery disease (CAD). We describe the methodology of the second FDA-mandated phase 3 prospective, open-label, international, multi-center trial of F-18 Flurpiridaz PET MPI.

methodsThe primary study end point is to assess the diagnostic efficacy of F-18 Flurpiridaz PET MPI in the detection of significant CAD [≥ 50% by quantitative invasive coronary angiography (ICA)] in patients with suspected CAD. The secondary endpoints are to evaluate the diagnostic efficacy of F-18 Flurpiridaz PET MPI compared to Tc-99 m-labeled SPECT MPI in the detection of CAD in all patients and in the following subgroups: (1) females; (2) patients with body mass index ≥ 30 kg/m

conclusionsThis second phase 3 study will provide additional evidence on the diagnostic efficacy of F-18 Flurpiridaz PET MPI in the detection of significant CAD. TRIAL REGISTRATION NUMBER: NCT03354273.

Indexed as

Myocardial Perfusion ImagingPositron-Emission TomographyPyridazinesClinical Trials, Phase III as TopicCoronary Artery DiseaseHumansMulticenter Studies as TopicResearch DesignBMS 747158-02PyridazinesCardiac PETCardiovascular imagingCoronary artery diseaseF-18 flurpiridazMyocardial perfusion imagingRadiotracers

Identifiers

PMID33521873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.